multiple sclerosis

With a new version of a low-cost eye-tracking system called EyeWriter, artists and others who are paralyzed due to amyotrophic lateral sclerosis (ALS) can more accurately draw and create images using only their eyes. The latest EyeWriter 2.0 software improves the system’s accuracy and now also allows the…

A new project run by a consortium of European institutions aims to improve the care of people with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) through targeted use of artificial intelligence (AI). Called BRAINTEASER, the four-year study will monitor some 300 participants using various wearable sensors and…

Denali Therapeutics and Sanofi announced a pause in clinical testing of their small molecule inhibitor DNL747 in favor of work on a possibly more effective compound, DNL788, for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s, and multiple sclerosis. DNL747 was seen to be safe…

Warning the reporter accompanying him not to take any pictures, veteran horticulturalist Michael Castleman punches an electronic code and unlocks the door to Room 209, nicknamed the “Mother Room.” Photography is indeed forbidden inside this living vault, which contains 20 phenotypes of cannabis plants thriving under the glare of 25…

Flex Pharma announced that it is stopping Phase 2 clinical trials of its investigational compound to ease muscle cramps, FLX-787, in patients with amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease (CMT). The company’s decision was based on tolerability concerns in each study with the oral disintegrating tablet formulation at 30…

A new portable system provides insights into the altered tongue, lip, and jaw motion in amyotrohic lateral sclerosis (ALS) patients with a speech disorder called dysarthria. The instrument could be valuable for both diagnosis and treatment of speech impairment. The study, “Articulatory Range of Movement…

There are some similarities between amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Both are diseases that attack the central nervous system, affecting the muscles and how you move your body. MORE: Find out about the early symptoms of ALS. They also both causes scarring around nerve…

MediciNova, Inc. announced its experimental therapy MN-166 (ibudilast) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with amyotrophic lateral sclerosis (ALS). The announcement arrived just after MediciNova presented positive interim data from ibudilast‘s ongoing clinical trial to evaluate the drug’s efficacy and…